A vaccine that targets 90 percent of all cancers shows promise in early clinical trials.
The Scientist
Most Recent
Lloyd Old, a researcher and former administrator of two cancer research institutes, passed away this week.
A genetically engineered smallpox vaccine improved the survival of liver cancer patients participating in a phase II clinical trial.
Page 1 of 1
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
